86 related articles for article (PubMed ID: 3050583)
1. [Cell kinetics of human meningiomas and neurinomas--Ki-67 PAP stain].
Shibata T; Burger PC; Kleihues P
No Shinkei Geka; 1988 Jul; 16(8):939-44. PubMed ID: 3050583
[TBL] [Abstract][Full Text] [Related]
2. Relationship between Ki-67 positive cells, growth rate and histological type of human intracranial tumors.
Patsouris E; Stocker U; Kallmeyer V; Keiditsch E; Mehraein P; Stavrou D
Anticancer Res; 1988; 8(4):537-44. PubMed ID: 3052245
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 immunoreactivity in meningiomas--determination of the proliferative potential of meningiomas using the monoclonal antibody Ki-67.
Madsen C; Schrøder HD
Clin Neuropathol; 1997; 16(3):137-42. PubMed ID: 9197938
[TBL] [Abstract][Full Text] [Related]
4. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
5. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas.
Torp SH; Lindboe CF; Granli US; Moen TM; Nordtømme T
Clin Neuropathol; 2001; 20(5):190-5. PubMed ID: 11594503
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
7. PCNA, Ki-67 and hTERT in residual benign meningiomas.
Maes L; Kalala JP; Cornelissen M; De Ridder L
In Vivo; 2006; 20(2):271-5. PubMed ID: 16634530
[TBL] [Abstract][Full Text] [Related]
8. [A family of von Recklinghausen's disease associated with bilateral acoustic neurinomas and falx meningiomas].
Araki Y; Imai S; Funakoshi T; Sakai N; Yamada H; Shimokawa K
No To Shinkei; 1984 Jul; 36(7):641-8. PubMed ID: 6435649
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies].
Miyagami M; Shibuya T; Miyagi A; Tsubokawa T
No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317
[TBL] [Abstract][Full Text] [Related]
11. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas.
Kim CH; Cheong JH; Bak KH; Kim JM; Oh SJ
J Clin Neurosci; 2001 May; 8 Suppl 1():44-8. PubMed ID: 11386825
[TBL] [Abstract][Full Text] [Related]
12. Potential doubling time and tumour doubling time in meningiomas and neurinomas.
Nakasu S; Nakasu Y; Nakajima M; Yokoyama M; Matsuda M; Handa J
Acta Neurochir (Wien); 1996; 138(6):763-70. PubMed ID: 8836295
[TBL] [Abstract][Full Text] [Related]
13. [An autopsy case of intracranial multiple meningiomas associated with extracranial multiple neurinomas].
Watanabe M; Watanabe Z; Sasaki T; Yamao N; Tanji H; Kodama N; Sato Y; Honda T; Endo S
No Shinkei Geka; 1984 Jul; 12(8):995-9. PubMed ID: 6435004
[TBL] [Abstract][Full Text] [Related]
14. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
Devaprasath A; Chacko G
Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
[TBL] [Abstract][Full Text] [Related]
16. [Cell kinetics of oligodendroglioma and oligo-astrocytoma--Ki-67 PaP study].
Shibata T; Burger PC; Kleihues P
No To Shinkei; 1988 Aug; 40(8):779-85. PubMed ID: 3052541
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
19. Clear cell meningioma. A clinicopathologic study of a potentially aggressive variant of meningioma.
Zorludemir S; Scheithauer BW; Hirose T; Van Houten C; Miller G; Meyer FB
Am J Surg Pathol; 1995 May; 19(5):493-505. PubMed ID: 7726360
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of HER2 expression in meningiomas: an immunohistochemical and fluorescence in situ hybridization study.
Loussouarn D; Brunon J; Avet-Loiseau H; Campone M; Mosnier JF
Hum Pathol; 2006 Apr; 37(4):415-21. PubMed ID: 16564915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
